Business Description
Destiny Pharma PLC
ISIN : GB00BDHSP575
Description
Destiny Pharma PLC is a clinical-stage biotechnology company that is focused on the development of medicines for the treatment of infectious diseases. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for the prevention of post-surgical staphylococcal infection, and NTCD-M3 among others.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.92 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 19.9 | |||||
| 3-Year EPS without NRI Growth Rate | 19.8 | |||||
| 3-Year FCF Growth Rate | 29.1 | |||||
| 3-Year Book Growth Rate | -22.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.95 | |||||
| 9-Day RSI | 40.75 | |||||
| 14-Day RSI | 37.81 | |||||
| 6-1 Month Momentum % | -75.51 | |||||
| 12-1 Month Momentum % | -39.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.89 | |||||
| Quick Ratio | 9.89 | |||||
| Cash Ratio | 8.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.8 | |||||
| Shareholder Yield % | -44.84 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -59.06 | |||||
| ROA % | -53.37 | |||||
| ROIC % | -194.65 | |||||
| ROC (Joel Greenblatt) % | -3177.36 | |||||
| ROCE % | -70.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.64 | |||||
| Price-to-Tangible-Book | 2.25 | |||||
| EV-to-EBIT | -1.29 | |||||
| EV-to-EBITDA | -1.29 | |||||
| EV-to-Forward-EBITDA | -11.31 | |||||
| EV-to-Forward-Revenue | 69.27 | |||||
| EV-to-FCF | -1.56 | |||||
| Price-to-Net-Current-Asset-Value | 2.25 | |||||
| Price-to-Net-Cash | 2.63 | |||||
| Earnings Yield (Greenblatt) % | -77.52 | |||||
| FCF Yield % | -36.93 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Destiny Pharma PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | |||
| EPS (TTM) (£) | -0.062 | ||
| Beta | -0.02 | ||
| Volatility % | 98.92 | ||
| 14-Day RSI | 37.81 | ||
| 14-Day ATR (£) | 0.010037 | ||
| 20-Day SMA (£) | 0.160375 | ||
| 12-1 Month Momentum % | -39.39 | ||
| 52-Week Range (£) | 0.13195 - 0.84 | ||
| Shares Outstanding (Mil) | 95.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Destiny Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Destiny Pharma PLC Stock Events
| Event | Date | Price(£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Destiny Pharma PLC Frequently Asked Questions
What is Destiny Pharma PLC(LSE:DEST)'s stock price today?
The current price of LSE:DEST is £0.16. The 52 week high of LSE:DEST is £0.84 and 52 week low is £0.13.
When is next earnings date of Destiny Pharma PLC(LSE:DEST)?
The next earnings date of Destiny Pharma PLC(LSE:DEST) is 2024-09-20 Est..
Does Destiny Pharma PLC(LSE:DEST) pay dividends? If so, how much?
Destiny Pharma PLC(LSE:DEST) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers